Navigation Links
Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that results available from its Phase 2 clinical trial of Hematide(TM) dosed monthly in dialysis patients were presented this week at the National Kidney Foundation (NKF) 2007 Spring Clinical Meeting. The results from this maintenance-switch trial in patients previously treated with three-times weekly Epoetin Alfa (EPO) demonstrated that mean hemoglobin (Hgb) levels can be maintained at clinically acceptable levels following a switch to once-monthly treatments with Hematide at an appropriate dosing regimen. The data were presented by Anatole Besarab, M.D., adjunct professor of Medicine, Wayne State University and director of Clinical Research at Henry Ford Hospital, Detroit in a poster session at the NKF meeting.

"These data are encouraging and show that patients can be switched from a regimen of EPO three-times weekly to once monthly Hematide in a controlled fashion where hemoglobin levels were maintained within 1 g/dL of baseline at an appropriate dosing regimen," said Dr. Besarab. This is especially important given the growing concerns related to excessive hemoglobin increases due to erythropoiesis stimulating agent use."

"We believe these data support the once per month dosing of Hematide and warrant further investigation in pivotal clinical studies," added Anne-Marie Duliege, M.D., vice president, Clinical, Medical and Regulatory Affairs at Affymax. "Based on the entire Phase 2 data set and as a result of our end of Phase 2 meetings with the Food and Drug Administration (FDA), we are preparing for Phase 3 clinical trials in patients on dialysis and not on dialysis. We are currently in discussions with the FDA on the design of this Phase 3 program."

The Phase 2 trial, which involved 165 patients, was an open label, multi-dose study conducted to assess safety, pharmacodynamics and pharmacokinetics of
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
2. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... DIEGO, Dec. 22, 2011 ViroPharma Incorporated (NASDAQ: ... exclusive option to acquire Meritage Pharma, Inc., a private company ... suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a ... has paid an initial $7.5 million, and has agreed to ...
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
Cached Medicine Technology:ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 2ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 4ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 5ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 6ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 7Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2
(Date:2/27/2015)... Laguna Hills, CA (PRWEB) February 27, 2015 ... has been chosen as their Sage ERP Document Management ... ERP, Sage 300 ERP, Sage CRM and other complimentary ... ADSS Global have worked side-by-side for many years to ... their Sage ERP applications. , “We are thrilled ...
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 On February ... “The Real Liquid Botox ,” that details the development ... that is working its way through FDA trials. For those ... cream is very attractive. Of course, if the drug ... prescription at a physician’s office. (see: goo.gl/PQvQwk) , “As the ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility ... (MMW) on the Upper East Side, was officially dedicated and ... His Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, ... and a member of the ArchCare Board of Trustees, presided ... O.Carm, executive director of MMW, and Christina McInerney, president and ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 The ... and research expertise have made it a beacon of ... and beyond, has been acknowledged by the national society ... the Huntington’s Disease Society of America — as ... , The acknowledgement recognizes the center’s service to over ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Is Topical Botox the Next Big Thing? 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... Diego, CA, August 2, 2011 Engaging in physical ... the odds of survival. In a study published in ... Preventive Medicine , researchers from the Israel Study Group ... (MI) survivors who lived in low socioeconomic status (SES) ...
... 29, 2011) − In a recent study published in ... University of Kentucky College of Nursing and Mark Pyles, ... at the College of Charleston, found smoke-free legislation does ... urban communities. This is true regardless of whether the ...
... -- Teens are much more likely to eat junk food ... with many fast food restaurants and other sources of unhealthy ... on junk food consumption by California teens living in neighborhoods ... food restaurants, convenience stores, dollar stores and liquor stores, with ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... after dinner. Play tag with your kids at the park. ... 150 minutes, or 2.5 hours, of moderate activity a week -- ... Those who did more -- about 300 minutes a week, ...
... Blocking a growth factor receptor cripples cancer growth in a ... online on August 1 in the Journal of Experimental ... cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic ... in aberrant activation of the cell. A study by Andrew ...
... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
Cached Medicine News:Health News:Heart attack survivors from poorer neighborhoods get less exercise 2Health News:Study finds smoke-free laws don't impact rural or urban economies 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:Even a Little Exercise Helps the Heart, Study Finds 2Health News:Even a Little Exercise Helps the Heart, Study Finds 3Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2
1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric...
... A-scan Sonomed-315 is intended for visualization of ... of midline shifts in the brain, evaluation ... easy to use, the Sonomed-315 offers quick ... mode allows to identify the anatomic structures ...
... a scaleable device that works ... platelet plasma or buffy coat. ... coat must be prepared independently ... Starting volume and concentration factor ...
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Medicine Products: